Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV-088 versus tamoxifen for breast cancer risk reduction in high-risk premenopausal women
ACTRN12625001263482Phase 2Not yet recruiting
- Sponsor
- Wellend Health
- Start
- Nov 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Tamoxifen with HAV-088 (2 arms). Primary endpoints: Change in qualitative background parenchymal enhancement and Change in quantitative background parenchymal enhancement. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
HAV-088tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12625001263482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001263482.